EXCLUSIVE: SAB Biotherapeutics Announces To Benzinga Presentation Of Safety And Pharmacologic Data From A GLP Toxicology Study For SAB-142
Portfolio Pulse from Benzinga Newsdesk
SAB Biotherapeutics announced the presentation of safety and pharmacologic data from a GLP toxicology study for SAB-142, a potential treatment for autoimmune and inflammatory diseases.
June 21, 2023 | 11:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SAB Biotherapeutics presented positive safety and pharmacologic data from a GLP toxicology study for SAB-142, which may boost investor confidence in the company.
The presentation of positive safety and pharmacologic data from a GLP toxicology study for SAB-142 indicates that the company is making progress in the development of a potential treatment for autoimmune and inflammatory diseases. This news may increase investor confidence in SAB Biotherapeutics and have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100